Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This phase III trial compares the effect of telotristat ethyl and the current standard of
care somatostatin analog therapy or somatostatin analog therapy alone in treating patients
with neuroendocrine tumor that has spread to other places in the body (metastatic).
Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and
carcinoid heart disease.